EXELIXIS INC (1EXEL.MI) Stock Price, Forecast & Analysis
BIT:1EXEL • US30161Q1040
1EXEL.MI Key Statistics, Chart & Performance
The current stock price of 1EXEL.MI is 30.7 EUR.
1EXEL.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1EXEL.MI.
1EXEL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to 1EXEL.MI. 1EXEL.MI gets an excellent profitability rating and is at the same time showing great financial health properties.
1EXEL.MI Financial Highlights
Over the last trailing twelve months 1EXEL.MI reported a non-GAAP Earnings per Share(EPS) of 1.8. The EPS increased by 67.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.01% | ||
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| Debt/Equity | 0 |
1EXEL.MI Forecast & Estimates
26 analysts have analysed 1EXEL.MI and the average price target is 38.31 EUR. This implies a price increase of 24.79% is expected in the next year compared to the current price of 30.7.
For the next year, analysts expect an EPS growth of 29.59% and a revenue growth 7.2% for 1EXEL.MI
1EXEL.MI Ownership
1EXEL.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.35 | 44.21B | ||
| 1AE | ARGENX SE | 28.19 | 44.16B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.038B | ||
| ABVX | ABIVAX SA | N/A | 8.73B | ||
| 2X1 | ABIVAX SA | N/A | 8.73B | ||
| GLPG | GALAPAGOS NV | N/A | 1.911B | ||
| GXE | GALAPAGOS NV | N/A | 1.911B | ||
| IVA | INVENTIVA SA | N/A | 1.108B | ||
| NANO | NANOBIOTIX | N/A | 1.106B | ||
| 6IV | INVENTIVA SA | N/A | 1.075B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1EXEL.MI
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA US
Employees: 1147
Phone: 16508377000
EXELIXIS INC / 1EXEL.MI FAQ
Can you describe the business of EXELIXIS INC?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Can you provide the latest stock price for EXELIXIS INC?
The current stock price of 1EXEL.MI is 30.7 EUR. The price decreased by -8.49% in the last trading session.
Does 1EXEL stock pay dividends?
1EXEL.MI does not pay a dividend.
How is the ChartMill rating for EXELIXIS INC?
1EXEL.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the analyst forecast for 1EXEL.MI stock?
26 analysts have analysed 1EXEL.MI and the average price target is 38.31 EUR. This implies a price increase of 24.79% is expected in the next year compared to the current price of 30.7.
What sector and industry does EXELIXIS INC belong to?
EXELIXIS INC (1EXEL.MI) operates in the Health Care sector and the Biotechnology industry.
What is EXELIXIS INC worth?
EXELIXIS INC (1EXEL.MI) has a market capitalization of 8.26B EUR. This makes 1EXEL.MI a Mid Cap stock.